Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.39 |
| ▸ | CTSS | P25774 | 2/20 | 0.38 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.34 |
| ▸ | SMO | Q99835 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | OGA | O60502 | 1/20 | 0.33 |
| ▸ | RORC | P51449 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4816824 | 0.86 | GRM5 (0.41) | KDM4ETSHRCTSSHRH4ALDH1A1 | |
| SCHEMBL4813294 | 0.83 | DRD2 (0.42) | KDM4ETSHRMCL1CTSSALDH1A1 | |
| SCHEMBL4816479 | 0.81 | MMP7 (0.51) | KDM4ETSHRMCL1CTSSHRH4 | |
| SCHEMBL4814260 | 0.74 | OGA (0.38) | KDM4ECTSSALDH1A1MAPTSMO | |
| SCHEMBL14252773 | 0.73 | MMP7 (0.51) | KDM4ETSHRCTSSALDH1A1MAPT | |
| SCHEMBL7358595 | 0.72 | MMP7 (0.38) | KDM4ETSHRCTSSHRH4ALDH1A1 | |
| SCHEMBL7362584 | 0.72 | GRM5 (0.35) | KDM4ECTSSHRH4ALDH1A1MAPT | |
| SCHEMBL4809675 | 0.72 | MMP7 (0.45) | CTSSALDH1A1MAPT | |
| SCHEMBL1266242 | 0.72 | HDAC1 (0.43) | KDM4ETSHRMCL1ALDH1A1MAPT | |
| SCHEMBL14252771 | 0.70 | MMP7 (0.53) | KDM4ECTSSALDH1A1MAPTSMO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7342020-B2 | Arylpiperazines and their use as metalloproteinase inhibiting agents (MMP) | ASTRAZENECA AB (SE) | 2008-03-11 | — | — | US | disclosed |
| EP-1109787-B1 | ARYLPIPERAZINES AND THEIR USE AS METALLOPROTEINASE INHIBITING AGENTS (MMP) | ASTRAZENECA AB (SE) | 2006-05-17 | — | — | EP | disclosed |
| US-20040171641-A1 | Arylpiperazines and their use as metalloproteinase inhibiting agents (MMP) | ASTRAZENECA AB (SE) | 2004-09-02 | — | — | US | disclosed |
| US-6734184-B1 | Arylpiperazines and their use as metalloproteinase inhibiting agents (MMP) | ASTRAZENECA AB (SE) | 2004-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040171641-A1 | Arylpiperazines and their use as metalloproteinase inhibiting agents (MMP) | MMP13, MMP25, MMP3 | KDM4E 2076/4885TSHR 2604/4885MCL1 837/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.